{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-RD7F7WO3/267608ea-fa98-4ec4-adb0-14450096fbe3/HTML","dcterms:extent":"41 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-RD7F7WO3/1f5cdc3c-d106-4c85-b578-1ee5f82c8ef6/PDF","dcterms:extent":"350 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-RD7F7WO3/3c4750a7-4616-4f1b-a197-23402399592d/TEXT","dcterms:extent":"38 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-RD7F7WO3","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2008","dc:creator":"Bratkovič, Tomaž","dc:format":[{"@xml:lang":"sl","#text":"številka:2"},{"@xml:lang":"sl","#text":"letnik:59"},{"@xml:lang":"sl","#text":"8 strani"},{"@xml:lang":"sl","#text":"str. 47-54"}],"dc:identifier":["ISSN:0014-8229","COBISSID:2326385","URN:URN:NBN:SI:doc-RD7F7WO3"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"biološka zdravila"},{"@xml:lang":"sl","#text":"Crohnova bolezen"},{"@xml:lang":"sl","#text":"črevesne bolezni"},{"@xml:lang":"en","#text":"therapy"},{"@xml:lang":"sl","#text":"ulcerozni kolitis"},{"@xml:lang":"sl","#text":"zdravljenje"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Biološke učinkovine pri zdravljenju Crohnove bolezni in ulceroznega kolitisa| Biologic agents in treatment of Crohn's disease and ulcerative colitis|"},"dc:description":[{"@xml:lang":"sl","#text":"Crohn's disease and ulcerative colitis (conditions together known as inflammatory bowel disease) are chronic inflammatory diseases affecting the bowel, whose causes remain unknown. In the last decades, however, our understanding of the pathophysiology of these conditions has enormously advanced. Conventional treatment of inflammatory bowel disease largely relies on the use of anti-inflammatory or immunosuppressive drugs that tend to act rather nonspecifically, often causing severe adverse effects that can even result in discontinuation of treatment. It is thus clear that development of safer and more effective drugs selectively blocking the inflammatory cascade is needed. In the European Union and the United States two and three biologic agents, respectively have already been approved for the management of Crohnćs disease and ulcerative colitis unresponsive to conventional treatment and development of several more is on the way. This review reports on current status of biological therapy for inflammatory bowel disease"},{"@xml:lang":"sl","#text":"Crohnova bolezen in ulcerozni kolitis sta dve obliki kronične vnetne črevesne bolezni. V zadnjih desetletjih je razumevanje njune patofiziologije močno napredovalo, a etiologija še vedno ostaja nepojasnjena. Konvencionalno farmakološko zdravljenje kronične vnetne črevesne bolezni sloni na uporabi neselektivno delujočih protivnetnih in/ali imunosupresivnih učinkovin, kar pri številnih bolnikih izzove neželene učinke ali celo resne iatrogene zaplete. Razvoj novih, varnejših in učinkovitejših zdravil, ki bi selektivno zavirala kaskadne reakcije vnetja, je ne le dobrodošel, temveč potreben. V Evropski uniji je trenutno za zdravljenje hudih oblik Crohnove bolezni in ulceroznega kolitisa, neodzivnih na običajno zdravljenje, odobrena uporaba dveh biolookih zdravil (v Združenih državah Amerike je nedavno dovoljenje za promet pridobilo že tretje), v različnih stopnjah kliničnih raziskav pa se jih nahaja še nekaj. Pričujoči pregledni članek povzema trenutno stanje bioloških zdravil za zdravljenje kronične vnetne črevesne bolezni"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-RD7F7WO3","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-RD7F7WO3"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-RD7F7WO3/1f5cdc3c-d106-4c85-b578-1ee5f82c8ef6/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-RD7F7WO3/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-RD7F7WO3"}}}}